LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Publication

A new era in aneuploidy screening: cfDNA testing in >30,000 multifetal gestations: Experience at one clinical laboratory

Brittany Dyr, Theresa Boomer, Eyad A. Almasri, Jenna L. Wardrop, Jill Rafalko, Jason Chibuk, Ron M. McCullough

Aneuploidy screening options are limited for multifetal pregnancies but a recent meta-analysis has shown that cfDNA for Trisomy 21 is superior to conventional screening in this population (Reference obgyn.onlinelibrary.wiley.com/doi/full/10.1002/uog.20284).

Our new study “A new era in aneuploidy screening: cfDNA testing in >30,000 multifetal gestations: experience at one clinical laboratory” details our extensive clinical laboratory experience with MaterniT21 PLUS screening in twins, triplets and higher order multiples.